Summary by Moomoo AI
On January 8, 2024, bluebird bio, Inc., a biotechnology company specializing in gene therapies, reported a preliminary unaudited cash, cash equivalents, and marketable securities balance of approximately $275 million as of December 31, 2023. This figure includes restricted cash of about $53 million. The announcement was made in a press release furnished as Exhibit 99.1 to the company's Current Report on Form 8-K filed with the SEC. The financial information is subject to the completion of financial closing procedures and has not been audited or reviewed by the company's independent registered public accounting firm. Additionally, bluebird bio plans to present a corporate update at the J.P. Morgan Healthcare Conference on January 9, 2024, with details provided in Exhibit 99.2. The company's cash position is expected to...Show More